Healthy Participants
Conditions
Brief summary
This randomized study will evaluate the safety, tolerability ,pharmacokinetics, pharmacodynamics and Immunogenicity of single ascending intramuscularly administered doses of HZBio1 in healthy volunteers.
Interventions
DRUGHZBio1 0.96mg / kg
HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
DRUGHZBio1 3mg / kg
HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
DRUGHZBio1 6mg / kg
HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
DRUGHZBio1 9mg / kg
HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
DRUGHZBio1 12mg / kg
HZBio1 will be administered intramuscularly in single ascending doses with starting of 0.96 mg/kg and subsequent doses of 3.0 mg/kg, 6.0 mg/kg ,9.0 mg/kg,and 12mg/kg, respectively.
DRUGPlacebo
Matching placebo will be administered intramuscularly.
Sponsors
Peking Union Medical College Hospital
Hangzhou Grand Biologic Pharmaceutical, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
1. Fully informed and signed informed consent form; 2. Healthy subjects, male and female; 3. At the time of signing the informed consent, they were over 18-45 years old (including 18 and 45 years old) and weighed more than 50 kg, Body mass index ranged from 19 to 26 (including 19 and 26) \[body mass index (BMI) = body weight (kg) / height 2 (M2)\]; 4. The results of serum pregnancy test in women of childbearing age were negative; 5. The subjects agreed to use effective contraception or abstinence during the study period and within 6 months after the end of the study; 6. Be able to understand and comply with the clinical protocol requirements, and it is expected to complete the whole trial process.
Exclusion criteria
1. History of hypertension or abnormal blood pressure at screening / baseline (SBP \> 140 mmHg and / or DBP \> 90 mmHg confirmed twice a day) 2. According to the researcher's judgment (clinical urine routine examination, proteinuria 2 + and above), proteinuria or proteinuria history with clinical significance. 3. Any previous VEGF and VEGFR antibody or protein therapy within one year. 4. No biological products or live virus vaccine shall be used for treatment for 3 months before the first administration of the study drug, or any monoclonal antibody shall be used for 12 months. 5. History or evidence of hereditary bleeding, coagulopathy, or thrombosis. 6. History of gastrointestinal perforation or fistula. 7. Severe, unhealed wounds, active ulcers, or untreated fractures, or were randomly assigned or expected to require major surgery during the course of the study or within 2 months after the last administration of the study drug. 8. RX or OTC drugs or nutritional supplements were used within 5 half lives before the first administration of the study drug or within 2 weeks (depending on the longer period). Herbal supplements need to be discontinued 28 days before the first administration of the study drug. 9. HBsAg, HCV antibody, HIV antibody and syphilis were positive 10. Known allergy to bevacizumab or any excipient 11. Known allergic diseases or allergic constitution 12. There was a history of unpaid blood donation within 3 months before taking the study drug for the first time 13. Use any other study drug for treatment or participate in other clinical trials within 3 months before screening 14. There was a history of alcohol or drug abuse within 12 months before screening; subjects were not able to control within 72 hours before and throughout the study 15. History of mental illness 16. During the study, the partner was expected to be pregnant. 17. During the study period, it did not conform to the clinical study protocol. 18. Other conditions not suitable for this study were considered by the researchers
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| serum uric acid level | 36 days | The decrease of serum uric acid level after administration will be analyzed. |
| Number of Participants Positive for Nab（Neutralizing Antibody） | 36 days | The changes of neutralizing antibody were observed before and after treatment. |
| Number of anti peg antibody | 36 days | The changes of anti peg antibody were observed before and after treatment. |
| Number of anti PHC antibody | 36 days | The changes of anti PHC antibody were observed before and after treatment. |
| AUC0-t of HZBio1 | 36 days | AUC0-t of HZBio1 (the area under the Concentration vs. Time curve from 0 to t post-infusion) |
| Percentage of Participants With Adverse Events (AEs) | 36 days | An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. |
| Tmax of HZBio1 | 36 days | Time to peak (Tmax) |
| Cmax of HZBio1 | 36 days | peak concentration (Cmax) |
| Кel of HZBio1 | 36 days | Кel of HZBio1 (elimination constant) |
| Т1/2 of HZBio1 | 36 days | Т1/2 of HZBio1 (half-life) |
Countries
China
Outcome results
None listed